Literature DB >> 8818725

Phase I study of recombinant CEA vaccinia virus vaccine with post vaccination CEA peptide challenge.

D J Cole1, M C Wilson, P L Baron, P O'Brien, C Reed, K Y Tsang, J Schlom.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8818725     DOI： 10.1089/hum.1996.7.11-1381

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN： 1043-0342            Impact factor:   5.695


× No keyword cloud information.
  6 in total

Review 1.  Library screening and receptor-directed targeting of gammaretroviral vectors.

Authors:  Peter M Mazari; Monica J Roth
Journal:  Future Microbiol       Date:  2013-01       Impact factor: 3.165

2.  Increased expression of CEA and MHC class I in colorectal cancer cell lines exposed to chemotherapy drugs.

Authors:  Shunroh Ohtsukasa; Satoshi Okabe; Hironori Yamashita; Takehisa Iwai; Kenichi Sugihara
Journal:  J Cancer Res Clin Oncol       Date:  2003-10-15       Impact factor: 4.553

Review 3.  Vaccines for pancreatic cancer.

Authors:  Kevin C Soares; Lei Zheng; Barish Edil; Elizabeth M Jaffee
Journal:  Cancer J       Date:  2012 Nov-Dec       Impact factor: 3.360

4.  T cell avidity and tumor recognition: implications and therapeutic strategies.

Authors:  Mark D McKee; Jeffrey J Roszkowski; Michael I Nishimura
Journal:  J Transl Med       Date:  2005-09-20       Impact factor: 5.531

Review 5.  Gene therapy for lung cancer.

Authors:  Eric B Haura; Eduardo Sotomayor; Scott J Antonia
Journal:  Mol Biotechnol       Date:  2003-10       Impact factor: 2.860

Review 6.  Oncolytic viruses: a new class of immunotherapy drugs.

Authors:  Howard L Kaufman; Frederick J Kohlhapp; Andrew Zloza
Journal:  Nat Rev Drug Discov       Date:  2015-09       Impact factor: 84.694
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.